RS 2135: structure given in first source; RN given refers to (mono-HCl;3aR-(3aalpha,12alpha,12aalpha,12balpha)-isomer); RN for parent cpd without isomeric designation not available 3/93
ID Source | ID |
---|---|
PubMed CID | 159591 |
CHEMBL ID | 556801 |
MeSH ID | M0198761 |
Synonym |
---|
133775-36-7 |
isoquino(2,1,8-1ma)carbazol-5(1h)-one, 12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydroxy-, monohydrochloride,(3ar-(3aalpha,12alpha,12aalpha,12balpha))- |
rs 2135 |
CHEMBL556801 |
(3ar,12r,12ar,12bs)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydroxy isoquino [2,1,8-lma]carbazol-5(1h)-one hydrochloride |
DTXSID70928267 |
12-amino-10-hydroxy-2,3,3a,4,11,12,12a,12b-octahydroisoquinolino[2,1,8-lma]carbazol-5(1h)-one--hydrogen chloride (1/1) |
(10r,11r,15r,19s)-10-amino-6-hydroxy-1-azapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18)-tetraen-17-one;hydrochloride |
(3ar,3a1s,12r,12ar)-12-amino-10-hydroxy-2,3,3a,3a1,4,11,12,12a-octahydroisoquinolino[2,1,8-lma]carbazol-5(1h)-one hydrochloride |
AKOS040747434 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID112265 | Antiarrhythmic activity in chloroform induced ventricular arrhythmia in mice, 15 min before exposure to chloroform intraperitoneal administration | 1992 | Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5 | Synthesis and biological action of the aminotetrahydroisoquinocarbazoles and related compounds: a new class of compounds with antiarrhythmic activity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (85.71) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.10) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |